Mineralys Therapeutics, Inc. Common Stock (MLYS NASDAQ) stock market data APIs
$37.5163
0.26(0.7%)
as of September 17, 2025
Try our APIs with
free plan!
Mineralys Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Prev. Close
37.5163
Open
37.7727
High
39.165
Low
37.0122
52 wk Range
8.241-39.2
Market Cap
2 893 M
Shares Outstanding
77 570 K
EPS
-0.66
Beta
-0.296
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mineralys Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mineralys Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Mineralys Therapeutics, Inc. Common Stock Fundamental Data
Mineralys Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -203 008 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Mineralys Therapeutics, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.74
Get Mineralys Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mineralys Therapeutics, Inc. Common Stock News
New
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
Key Points Over the past month, small cap stocks have gone from out-of-favor to market leaders. Expected rate cuts are at the center of the move, but there's a lot more to it than that. Even small c...
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
Key Points Over the past month, small cap stocks have gone from out-of-favor to market leaders. Expected rate cuts are at the center of the move, but there's a lot more to it than that. Even small ca...
SA Asks: Which biotechs could be acquired by year's end?
[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a signifi...
Mineralys Therapeutics Reaches Analyst Target Price
In recent trading, shares of Mineralys Therapeutics Inc (Symbol: MLYS) have crossed above the average analyst 12-month target price of $38.25, changing hands for $38.50/share. When a stock reaches th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
